Last reviewed · How we verify
Surfaxin (LUCINACTANT)
At a glance
| Generic name | LUCINACTANT |
|---|---|
| Sponsor | Discovery Labs |
| Drug class | lucinactant |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
| First approval | 2012 |
Approved indications
- Respiratory distress syndrome in the newborn
Common side effects
Key clinical trials
- The Safety and Preliminary Tolerability of Lyophilized Lucinactant in Adults With Coronavirus Disease 2019 (COVID-19) (PHASE2)
- A Safety and Efficacy Study of Lucinactant for Inhalation in Preterm Neonates 26 to 32 Weeks Gestational Age (PHASE2)
- The Safety and Efficacy of Lucinactant for Inhalation in Premature Neonates 26 to 32 Weeks Gestational Age (PHASE2)
- Trial To Assess The Safety And Tolerability Of Lucinactant For Inhalation In Preterm Neonates 26 to 28 Weeks PMA (PHASE2)
- KL₄Surfactant Treatment in Patients With ARDS (PHASE2)
- Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates (PHASE2)
- Effect of Lucinactant on Mucus Clearance in Cystic Fibrosis Lung Disease (PHASE2)
- Feasibility Study of Aerosolized Surfaxin in the Prevention of Respiratory Distress Syndrome (RDS) in Premature Infants (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |